Cardiovascular endocrinology: RAGE--a biomarker for CHD in T2DM?

摘要

High levels of two isoforms of RAGE (receptor for advanced glycation end products) are associated with an increased risk of incident coronary heart disease (CHD) in patients with type 2 diabetes mellitus (T2DM), reveal new data of a nested case-control study.RAGE binds a number of ligands including advanced glycation end products, and this process is implicated in the development of cardiovascular disease in patients with T2DM. Colhoun et al. set out to test whether the soluble (sRAGE) or the secreted (esRAGE) isoforms of RAGE could predict future CHD events and stroke in this patient group.The researchers measured pre-randomization serum levels of the two isoforms of RAGE in samples taken from patients with T2DM who were enrolled in a previous trial of statin therapy and who experienced incident cardiovascular events during a median follow up of 3.9 years.